Skip to content

Application of esketamine in complete curettage of uterine cavity

The optimal dose of propofol combined with esketamine in complete curettage of uterine cavity

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050889
Enrollment
Unknown
Registered
2021-09-07
Start date
2021-09-08
Completion date
Unknown
Last updated
2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early pregnancy

Interventions

Group 1:Esketamine
Control group:Nil

Sponsors

The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary painless abortion; 2. Aged 18-40 years, body mass index 20-30 kg/m^2; 3. ASA grade I-II; 4. Intrauterine pregnancy for 40-70 days; 5. No previous respiratory and circulatory diseases; 6. Neurological and mental diseases and drug dependence; 7. Normal liver and kidney function; 8. No hearing impairment; 9. No sedative and analgesic drugs before operation.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to ketamine, esmketamine, fentanyl and propofol; 2. Contraindications to ESM ketamine, such as intractable, refractory hypertension, serious cardiovascular disease and hyperthyroidism; 3. Patients who refused to participate in the study; 4. Patients with operation time greater than 5 minutes.

Design outcomes

Primary

MeasureTime frame
Motion;

Countries

China

Contacts

Public ContactXu Tao

The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong UniversityMedicine, Shanghai Jiao Tong University

18918098660@163.com+86 18918098660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026